REKA.TA TLV
Rekah Pharmaceutical Industry Ltd.
1W: -0.1%
1M: +12.5%
3M: +11.9%
YTD: -1.1%
1Y: -2.2%
3Y: -29.5%
5Y: -50.0%
₪1,145.00 ($3.76)
-31.00 (-2.64%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$322M
+0.0% ▲
5Y CAGR: +10.4%
Gross Profit
$72M
-10.3% ▼
5Y CAGR: +3.3%
Operating Income
$16M
+453.8% ▲
5Y CAGR: +7.3%
Net Income
$6M
+189.8% ▲
5Y CAGR: +9.9%
EPS (Diluted)
$0.52
+185.2% ▲
5Y CAGR: +16.7%
EBITDA
$47M
+81.7% ▲
5Y CAGR: +12.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $265M | $264M | $292M | $322M | $322M |
| YoY Growth | +35.1% | -0.6% | +10.8% | +10.0% | +0.0% |
| Cost of Revenue | $197M | $199M | $214M | $241M | $250M |
| Gross Profit | $69M | $65M | $79M | $80M | $72M |
| Gross Margin | 25.9% | 24.7% | 26.9% | 24.9% | 22.4% |
| R&D Expenses | $2M | $2M | $3M | $4M | $4M |
| SG&A Expenses | $8M | $10M | $13M | $71M | $16M |
| Operating Expenses | $48M | $51M | $65M | $77M | $56M |
| Operating Income | $21M | $14M | $13M | $3M | $16M |
| Operating Margin | 7.9% | 5.4% | 4.5% | 0.9% | 5.1% |
| Interest Expense | $6M | $6M | $6M | $10M | $7M |
| Income Before Tax | $14M | $8M | $357K | -$7M | $8M |
| Tax Expense | $3M | $1M | $2M | -$138K | $2M |
| Net Income | $11M | $7M | -$2M | -$7M | $6M |
| Net Margin | 4.1% | 2.5% | -0.7% | -2.1% | 1.9% |
| EPS (Diluted) | $0.95 | $0.58 | $-0.18 | $-0.61 | $0.52 |
| EBITDA | $40M | $36M | $41M | $26M | $47M |
| Shares Outstanding | 11M | 11M | 11M | 11M | 12M |